Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture - Conditioned medium

Clinical Chemistry

Volumn 53, Issue 3, 2007, Pages 429-437

  Sardana, Girish ^a,b,c   Marshall, John ^d   Diamandis, Eleftherios P ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d RYERSON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; KALLIKREIN; KALLIKREIN 11; KALLIKREIN 5; KALLIKREIN 6; MAC 2 BINDING PROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CULTURE MEDIUM; ELECTROSPRAY MASS SPECTROMETRY; GENOME; HUMAN; HUMAN CELL; IMMUNOASSAY; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEOMICS;

ANTIGENS, NEOPLASM; CARRIER PROTEINS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; FALSE POSITIVE REACTIONS; GLYCOPROTEINS; HUMANS; IMMUNOASSAY; KALLIKREINS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEOME; PROTEOMICS; SERINE ENDOPEPTIDASES; SOFTWARE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 33947357719     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.077370     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, et al. The case for early detection. Nat Rev Cancer 2003;3:243-52.
3. Duffy MJ. Evidence for the clinical use of tumour markers. Ann Clin Biochem 2004;41:370-7.
4. Ryan CJ, Small EJ. Prostate cancer update: 2005. Curr Opin Oncol 2006;18:284-8.
5. Schmid HP, Riesen W, Prikler L. Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 2004;50:71-8.
6. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004;171:2239-44.
7. Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, et al. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. J Urol 2005;173: 752-6.
8. Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 2002;59:2-8.
9. Ciatto S, Bonardi R, Mazzotta A, Lombardi C, Santoni R, Cardini S, et al. Comparing two modalities of screening for prostate cancer: digital rectal examination + transrectal ultrasonography vs. prostate-specific antigen. Tumori 1995;81:225-9.
10. Semmes OJ, Malik G, Ward M. Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer. J Cell Biochem 2006;98:496-503.
11. Petricoin EF III, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8.
12. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-6.
13. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-78.
14. Stamey TA. The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the U S A. BJU Int 2004;94:963-4.
15. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-43.
16. Scaros O, Fisler R. Biomarker technology roundup: from discovery to clinical applications, a broad set of tools is required to translate from the lab to the clinic. Biotechniques 2005;Suppl:30-2.
17. Jacobs JM, Adkins JN, Qian WJ, Liu T, Shen Y, Camp DG, et al. Using human blood plasma for proteomic biomarker discovery. J Proteome Res 2005;4:1073-85.
18. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004;3:311-26.
19. Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, Scorilas A, et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003;63: 3958-65.
20. Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003;21:1035-43.
21. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai AR, Diamandis EP. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 2003;63:6543-6.
22. Christopoulos TK, Diamandis EP. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 1992;64:342-6.
23. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-9.
24. Diamandis EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 2002;62:295-300.
25. Roy I, Gupta MN. Freeze-drying of proteins: some emerging concerns. Biotechnol Appl Biochem 2004;39:165-77.
26. Annesley TM. Ion suppression in mass spectrometry. Clin Chem 2003;49:1041-4.
27. Fornarini B, D'Ambrosio C, Natoli C, Tinari N, Silingardi V, Iacobelli S. Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood 2000;96:3282-5.
28. Ozaki Y, Kontani K, Teramoto K, Fujita T, Tezuka N, Sawai S, et al. Involvement of 90K/Mac-2 binding protein in cancer metastases by increased cellular adhesiveness in lung cancer. Oncol Rep 2004;12:1071-7.
29. Iacobelli S, Sismondi P, Giai M, D'Egidio M, Tinari N, Amatetti C, et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer 1994;69:172-6.
30. Iacovazzi PA, Guerra V, Elba S, Sportelli F, Manghisi OG, Correale M. Are 90K/MAC-2BP serum levels correlated with poor prognosis in HCC patients? Preliminary results. Int J Biol Markers 2003;18: 222-6.
31. Zeimet AG, Natoli C, Herold M, Fuchs D, Windbichler G, Daxenbichler G, et al. Circulating immunostimulatory protein 90K and soluble interleukin-2- receptor in human ovarian cancer. Int J Cancer 1996;68:34-8.
32. Greco C, Vona R, Cosimelli M, Matarrese P, Straface E, Scordati P, et al. Cell surface overexpression of galectin-3 and the presence of its ligand 90k in the blood plasma as determinants in colon neoplastic lesions. Glycobiology 2004;14:783-92.
33. Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominate P, et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004;19:551-6.
34. Bair EL, Nagle RB, Ulmer TA, Laferte S, Bowden GT. 90K/Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression. Prostate 2006;66:283-93.
35. Volmer MW, Stuhler K, Zapatka M, Schoneck A, Klein-Scory S, Schmiegel W, et al. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 2005;5:2587-601.
36. Martin DB, Gifford DR, Wright ME, Keller A, Yi E, Goodlett DR, et al. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004;64:347-55.
37. Lin B, White JT, Lu W, Xie T, Utleg AG, Yan X, et al. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res 2005;65:3081-91.